Company Overview and News
Stop missing out on important events!
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) has 22 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,199,114 shares. Largest shareholders include Montreux Equity Partners V, L.p., Bard Associates Inc, Vanguard Group Inc, Renaissance Technologies LLC, JW Asset Management, LLC, BlackRock Inc. (48-0)
BOCA RATON, FL / ACCESSWIRE / March 7, 2018 / Dawson James Securities, Inc. in conjunction with Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, Warrants - SNOAW) today announced the March 6th closing of a public offering of 1,428,570 shares of common stock at an offering price of $3.50. SNOA Nasdaq closing bid on the day of pricing was $3.51. (10-0)
* SONOMA PHARMACEUTICALS INC - ANNOUNCED CLOSING OF PUBLIC OFFERING OF 1,428,570 SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $3.50 PER SHARE Source text for Eikon: Further company coverage: (10-0)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (10-0)
Filed Pursuant to Rule 424(b)(3) Registration No. 333-221477 PROSPECTUS SUPPLEMENT (to Prospectus dated November 28, 2017) (10-0)
The information in this prospectus supplement is not complete and may be changed. This prospectus supplement is not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any state where the offer or sale is not permitted. (10-0)
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION< (10-0)
Today we will focus on Adamas Pharmaceuticals (ADMS). On Thursday, the company reported data from the EASE LID 2 study. (166-7)
Good afternoon, and welcome to the Sonoma Fiscal Third Quarter 2018 Conference Call. My name is Amanda, and I'll be your coordinator for today's call. At this time, all participants are in a listen-only mode. At the end of the call, we will be holding a question-and-answer session with company management. As a reminder, this call is being recorded for replay purposes. (10-0)
The following slide deck was published by Sonoma Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings call. (10-0)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2018 SONOMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33216 68-0423298 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.
November 16, 2017 Jim Schutz Chief Executive Officer Sonoma Pharmaceuticals, Inc. 1129 N. McDowell Blvd. Petaluma, California 94954 Sonoma Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 9, 2017 File No. 333-221477 Re: Dear Mr. Schutz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration.
November 21, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 3561 Washington, D.C. 20549 Attn: Chris Edwards Re: Sonoma Pharmaceuticals, Inc. Registration Statement on Form S-3, as amended Filed November 9, 2017, and amended on November 17, 2017 File No. 333-221477 Acceleration Request Requested Date: November 27, 2017 Requested Time: 4:00 P.
Filed Pursuant to Rule 424(b)(3) Registration No. 333-221477 PROSPECTUS SUPPLEMENT (to Prospectus dated November 28, 2017) $5,000,000 SONOMA PHARMACEUTICALS, INC. COMMON STOCK We have entered into an At Market Issuance Sales Agreement which we refer to herein as the Sales Agreement, with B. Riley FBR, Inc. as the Sales Agent, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus.